Abstract
The inhibition of α-glucosidase and α-amylase, enzymes involved in the digestion of carbohydrates, can significantly reduce the post-prandial increase of blood glucose and therefore can be an important strategy in the management of blood glucose level in type 2 diabetic and borderline patients. Currently, there is renewed interest in plant-based medicines and functional foods modulating physiological effects in the prevention and cure of diabetes and obesity. The plant kingdom is a wide field to search for natural effective oral hypoglycaemic agents that have slight or no side effects. More than ca. 1200 plant species have been recorded to be used empirically worldwide for their alleged hypoglycaemic activity. Therefore, natural α-glucosidase and α-amylase inhibitors from plant sources offer an attractive strategy for the control of hyperglycaemia. This article reviews recent data on plant extracts and isolated natural compounds that are being tested for their hypoglycaemic activity, highlights ongoing research and considers the future perspectives.
Keywords: Diabetes, Post-prandial Hyperglycaemia, α-Glucosidase, α-Amylase, Extract, Natural compounds
Mini-Reviews in Medicinal Chemistry
Title: Natural Products as α-Amylase and α-Glucosidase Inhibitors and their Hypoglycaemic Potential in the Treatment of Diabetes: An Update
Volume: 10 Issue: 4
Author(s): R. Tundis, M.R. Loizzo and F. Menichini
Affiliation:
Keywords: Diabetes, Post-prandial Hyperglycaemia, α-Glucosidase, α-Amylase, Extract, Natural compounds
Abstract: The inhibition of α-glucosidase and α-amylase, enzymes involved in the digestion of carbohydrates, can significantly reduce the post-prandial increase of blood glucose and therefore can be an important strategy in the management of blood glucose level in type 2 diabetic and borderline patients. Currently, there is renewed interest in plant-based medicines and functional foods modulating physiological effects in the prevention and cure of diabetes and obesity. The plant kingdom is a wide field to search for natural effective oral hypoglycaemic agents that have slight or no side effects. More than ca. 1200 plant species have been recorded to be used empirically worldwide for their alleged hypoglycaemic activity. Therefore, natural α-glucosidase and α-amylase inhibitors from plant sources offer an attractive strategy for the control of hyperglycaemia. This article reviews recent data on plant extracts and isolated natural compounds that are being tested for their hypoglycaemic activity, highlights ongoing research and considers the future perspectives.
Export Options
About this article
Cite this article as:
Tundis R., Loizzo M.R. and Menichini F., Natural Products as α-Amylase and α-Glucosidase Inhibitors and their Hypoglycaemic Potential in the Treatment of Diabetes: An Update, Mini-Reviews in Medicinal Chemistry 2010; 10 (4) . https://dx.doi.org/10.2174/138955710791331007
DOI https://dx.doi.org/10.2174/138955710791331007 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Hypertension Induced Albuminuria
Current Pharmaceutical Design Chest Pain in Children
Current Pediatric Reviews The Metabolic Treatment of Patients with Coronary Artery Disease: Effects on Quality of Life and Effort Angina
Current Pharmaceutical Design Cerebrovascular and Blood-Brain Barrier Morphology in Spontaneously Hypertensive Rats: Effect of Treatment with Choline Alphoscerate
CNS & Neurological Disorders - Drug Targets Redox-Driven Events in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection and their Clinical Implications
Current HIV Research Potential Impact of MicroRNA-423 Gene Variability in Coronary Artery Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Exercise for the Overweight and Obese
Current Pharmaceutical Design Identification of Genes for a Complex Trait: Examples from Hypertension
Current Pharmaceutical Biotechnology Cardiovascular Implantable Electronic Device Infections: Risk Scoring and Role of Antibiotic Envelope in Prevention
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets A Direct Correlation between Red Blood Cell Indices and Cognitive Impairment After Aneurysmal Subarachnoid Hemorrhage (aSAH)
Current Neurovascular Research Subject index to volume 1
Current HIV Research Ascorbic Acid in Postoperative Intensive Care Patients - Biochemical Aspects and Clinical Experience
Current Medicinal Chemistry The Role of Hyperglycaemia and the Hypercoagulable State in the Pathogenesis of Cardiovascular Events in Diabetes Mellitus: Implications for Hypertension Management
Current Pharmaceutical Design Phosphodiesterases (PDEs) from Snake Venoms: Therapeutic Applications
Protein & Peptide Letters Psoriasis and Vascular Risk : An Update
Current Pharmaceutical Design Editorial [Hot topic:Current Hypertension Reviews, Hot Topics “Obesity, Hypertension, and the Metabolic Syndrome” (Guest Editor: Kazuko Masuo)]
Current Hypertension Reviews Alert Cell Strategy: Mechanisms of Inflammatory Response and Organ Protection
Current Pharmaceutical Design Insulin and the Brain
Current Diabetes Reviews Targeted Therapies in Hepatocellular Carcinoma
Current Medicinal Chemistry